← back to search

Wenming Chen

Wenzhou Medical University · CN
Area of research
Hematology · Materials Chemistry
Research interest
Research interests include Caffeic acid, Chemistry, Linker, Conjugate, Stereochemistry, and Denosumab.
h-index
citations
6
works
2
NIH funding
primary concept
email

Recent publications

CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple Myeloma
Journal of the National Comprehensive Cancer Network 2025cited by 0position: middledoi
Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives
Bioorganic Chemistry 2021cited by 6position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

· 1 papers (2025–2025)Baijun Fang · Zhengzhou University1 papers (2025–2025)Meizhu Wang · Guangzhou University of Chinese Medicine1 papers (2021–2021)Zhen Cai · Huazhong University of Science and Technology1 papers (2025–2025)Fang Zhou · Ministry of Education of the People's Republic of China1 papers (2021–2021)Juan Du · Harbin Medical University1 papers (2025–2025)Chunyan Sun · Union Hospital1 papers (2025–2025)Xiaobing Huang · University of Electronic Science and Technology of China1 papers (2025–2025)Wen Zhou · Guangzhou University of Chinese Medicine1 papers (2021–2021)Zhongjun Xia · Sun Yat-sen University1 papers (2025–2025)Jian Hou · Chinese Academy of Agricultural Sciences1 papers (2025–2025) · 1 papers (2025–2025)Honghui Huang · South China Agricultural University1 papers (2025–2025)Shuhao Mei · Fudan University1 papers (2025–2025)Chunrui Li · Renmin Hospital of Wuhan University1 papers (2025–2025)Fengyan Jin · Jilin University1 papers (2025–2025)Xiaoling Guo · Hebei Medical University1 papers (2025–2025)Hongming Huang · Nanchang University1 papers (2025–2025)Cui Zhou · Chinese Academy of Sciences1 papers (2021–2021)Hongfeng Ge · Anhui Medical University1 papers (2025–2025)